Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010839 | 1.00 | HSD17B10 (0.52) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1550543 | 1.00 | HSD17B10 (0.52) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1115598 | 1.00 | HSD17B10 (0.52) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| Methane SCHEMBL667082 | 0.98 | HSD17B10 (0.51) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL3434909 | 0.95 | HSD17B10 (0.48) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL12486284 | 0.95 | HSD17B10 (0.48) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1427524 | 0.95 | HSD17B10 (0.48) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL31459726 | 0.93 | HPGD (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| Methane SCHEMBL6697096 | 0.93 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL29126181 | 0.93 | HPGD (0.50) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120054230-A | Preparation method and application of covalent organic framework bipolar membrane | 浙江大学 | 2025-05-30 | — | — | CN | claimed |
| CN-115611857-A | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海伍夫科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | GOFF HILL LIMITED (BB) | 2012-02-09 | — | — | US | claimed |
| EP-2403496-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | Goff Hill Limited (BB) | 2012-01-11 | — | — | EP | claimed |
| WO-2010099600-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | TUCKER WILLIAM G (CA) | 2010-09-10 | — | — | WO | claimed |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| CN-120054230-A | Preparation method and application of covalent organic framework bipolar membrane | 浙江大学 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025094035-A1 | TOLL-LIKE RECEPTOR AGONISTS AND CONJUGATES THEREOF | PFIZER INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | YA THERAPEUTICS INC (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2024001839-A1 | HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
| US-6531598-B1 | Naphthostyrils | HOFFMANN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| US-6504034-B2 | Cell antiproliferative agents; anticancer agents | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| WO-2002085925-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020147343-A1 | Naphthostyrils | CHEN YI (US) | 2002-10-10 | — | — | US | disclosed |
| WO-2002059109-A2 | NAPHTHOSTYRIL DERIVATIVES AND THEIR USE AS INHIBITORS OF CYCLIN- DEPENDENT KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-01 | — | — | WO | disclosed |
| US-4634715-A | CONVERTING ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0058918-B1 | AZA ANALOGS OF AMINOACID DERIVATIVES AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1986-01-29 | — | — | EP | disclosed |
| EP-0058918-A1 | Aza analogs of aminoacid derivatives as antihypertensives | MERCK & CO. INC. (US) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | FGFR1, FGFR2, FGFR3 | HSD17B10 1223/4885CHRM2 4856/4885CHRM1 4874/4885 |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | CTNNB1, CTNND1, CTNNA1 | HSD17B10 1763/4885CHRM2 4789/4885CHRM1 4854/4885 |
| US-20020147343-A1 | Naphthostyrils | CCNI, CDKL1, CDK2 | HSD17B10 1394/4885CHRM2 4598/4885CHRM1 4510/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | HSD17B10 1763/4885CHRM2 4789/4885CHRM1 4854/4885 |
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | TP53, RNASE1, FURIN | HSD17B10 807/4885CHRM2 4846/4885CHRM1 4815/4885 |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | HSD17B10 3092/4885CHRM2 778/4885CHRM1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.